These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 2650404)

  • 21. Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation.
    Wong R; Shahjahan M; Wang X; Thall PF; De Lima M; Khouri I; Gajewski J; Alamo J; Couriel D; Andersson BS; Donato M; Hosing C; Komanduri K; Anderlini P; Molldrem J; Ueno NT; Estey E; Ippoliti C; Champlin R; Giralt S
    Biol Blood Marrow Transplant; 2005 Feb; 11(2):108-14. PubMed ID: 15682071
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bone marrow transplantation for myelodysplastic syndrome and secondary leukaemias.
    De Witte T; Gratwohl A
    Br J Haematol; 1993 Jul; 84(3):361-4. PubMed ID: 8217787
    [No Abstract]   [Full Text] [Related]  

  • 23. Frequent p53 overexpression in therapy related myelodysplastic syndromes and acute myeloid leukemias: an immunohistochemical study of bone marrow biopsies.
    Orazi A; Cattoretti G; Heerema NA; Sozzi G; John K; Neiman RS
    Mod Pathol; 1993 Sep; 6(5):521-5. PubMed ID: 8248107
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reticulated platelets as a marker of platelet recovery after allogeneic stem cell transplantation.
    Michur H; Maślanka K; Szczepiński A; Mariańska B
    Int J Lab Hematol; 2008 Dec; 30(6):519-25. PubMed ID: 18983304
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of autologous bone marrow transplantation for patients with acute and chronic leukemias.
    Geller RB
    Hematol Oncol Clin North Am; 1993 Jun; 7(3):547-75. PubMed ID: 8344882
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of a secondary myelodysplastic syndrome after allogenic bone marrow transplantation using Mylotarg.
    Hermida G; Manjón R; Rodríguez-Salazar I; Richard C
    Haematologica; 2002 Apr; 87(4):ECR14. PubMed ID: 11940496
    [No Abstract]   [Full Text] [Related]  

  • 27. Comparison of engraftment in recipients of matched sibling of unrelated donor marrow allografts.
    Davies SM; Ramsay NK; Haake RJ; Kersey JH; Weisdorf DJ; McGlave PB; Blazar BR
    Bone Marrow Transplant; 1994 Jan; 13(1):51-7. PubMed ID: 8019453
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Contemporaneous appearance, 18 years after allogeneic bone marrow transplantation, of myelodysplastic syndrome in the patient and the donor.
    Orciuolo E; Azzarà A; Bandini G; Galimberti S; Bonifazi F; Fazzi R; Petrini M
    Bone Marrow Transplant; 2004 Apr; 33(8):859-61. PubMed ID: 14743194
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Bone marrow transplantation for refractory anemia].
    Takemoto Y; Kanamaru A
    Rinsho Ketsueki; 1993 Mar; 34(3):289-93. PubMed ID: 8479079
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immune escape from a graft-versus-leukemia effect may play a role in the relapse of myeloid leukemias following allogeneic bone marrow transplantation.
    Dermime S; Mavroudis D; Jiang YZ; Hensel N; Molldrem J; Barrett AJ
    Bone Marrow Transplant; 1997 May; 19(10):989-99. PubMed ID: 9169643
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Allogeneic and autologous stem cell transplantation in myelodysplastic syndromes.
    De Witte T
    Pathol Biol (Paris); 1997 Oct; 45(8):643-9. PubMed ID: 9569930
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of allogeneic bone marrow transplantation for the treatment of myelodysplastic syndromes in childhood. The European Working Group on Childhood Myelodysplastic Syndrome (EWOG-MDS) and the Austria-Germany-Italy (AGI) Bone Marrow Transplantation Registry.
    Locatelli F; Zecca M; Niemeyer C; Angelucci E; Arcese G; Bender-Gotze C; Bonetti F; Burdach S; Dini G; Ebell W; Friedrich W; Hasle H; Hermann J; Jacobsen N; Klingebiel T; Kremens B; Mann G; Miniero R; Pession A; Peters C; Paolucci P; Rossetti F; Schmid HJ; Stary J; Zimmermann M
    Bone Marrow Transplant; 1996 Nov; 18 Suppl 2():63-8. PubMed ID: 8932802
    [No Abstract]   [Full Text] [Related]  

  • 33. [Donor cell-derived acute myeloid leukemia developed shortly after allogeneic bone marrow transplantation for MDS overt leukemia].
    Takahashi R; Shimazaki C; Inaba T; Nakagawa M; Yamaoka M
    Rinsho Ketsueki; 2002 Oct; 43(10):963-5. PubMed ID: 12462035
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reconstitution of T cell subset repertoire diversity following multiple antigen-mismatched bone marrow transplantation.
    Friedman TM; Azhipa O; Zilberberg J; Tkachuk Y; Hsu JW; Rowley SD; Goldberg SL; Korngold R; Pecora AL; Preti RA
    Biol Blood Marrow Transplant; 2006 Oct; 12(10):1092-5. PubMed ID: 17084373
    [No Abstract]   [Full Text] [Related]  

  • 35. Incidence and characterization of secondary myelodysplastic syndromes following autologous transplantation.
    Del Cañizo Mf; Amigo Mf; Hernández JM; Sanz G; Núñez R; Carreras E; Alegre A; Cuesta B; Mataix R
    Haematologica; 2000 Apr; 85(4):403-9. PubMed ID: 10756367
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Allogeneic bone marrow transplantation for children with acute leukemia: long-term follow-up of patients prepared with high-dose cytosine arabinoside and fractionated total body irradiation.
    Gordon BG; Warkentin PI; Strandjord SE; Abromowitch M; Bayever E; Harper JL; Coccia PF
    Bone Marrow Transplant; 1997 Jul; 20(1):5-10. PubMed ID: 9232249
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Therapy-related myelodysplastic syndrome and acute myeloid leukemia after autologous bone marrow transplantation: dosis facit venenum?
    Sill H; Olipitz W; Schimek MG
    J Clin Oncol; 2005 Nov; 23(31):8120-1; author reply 8121-2. PubMed ID: 16258113
    [No Abstract]   [Full Text] [Related]  

  • 38. Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome.
    Alyea EP; Kim HT; Ho V; Cutler C; DeAngelo DJ; Stone R; Ritz J; Antin JH; Soiffer RJ
    Biol Blood Marrow Transplant; 2006 Oct; 12(10):1047-55. PubMed ID: 17067911
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Topical cyclosporin A for treatment of oral chronic graft-versus-host disease.
    Epstein JB; Reece DE
    Bone Marrow Transplant; 1994 Jan; 13(1):81-6. PubMed ID: 8019458
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of tumor necrosis factor alpha in acute graft-versus-host disease and complications following allogeneic bone marrow transplantation.
    Holler E; Kolb HJ; Hintermeier-Knabe R; Mittermüller J; Thierfelder S; Kaul M; Wilmanns W
    Transplant Proc; 1993 Feb; 25(1 Pt 2):1234-6. PubMed ID: 8442099
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.